CAR-T Meeting 2024 | Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the findings of a retrospective analysis conducted by the EBMT Acute Leukemia Working Party (ALWP), which compared the outcomes of patients with secondary and de-novo acute lymphoblastic leukemia (ALL) who underwent allogeneic stem cell transplantation (alloSCT). Despite the traditional belief that patients with secondary ALL have a worse prognosis, this study elucidated that outcomes in the two groups were comparable. Prof. Mohty highlights that based on these findings, patients with secondary disease should be considered for transplant wherever possible. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer; Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
